HONG KONG SAR- Media OutReach Newswire - 12 June 2025 - According to data from the Hong Kong Cancer Registry of the Hospital Authority¹, the overall five-year survival rate for cancer patients has increased from 42% in the early 2000s to 55% in recent years, reflecting the importance of early cancer detection and appropriate treatment. FWD Hong Kong ("FWD"), Roche Diagnostics (Hong Kong) Limited ("Roche Diagnostics"), and HKSH Cancer Centre ("HKSH") are joining forces to enhance public awareness of precision cancer medicine. Information on Comprehensive Genomic Profiling ("CGP") and precision medicine in cancer treatment will be introduced through FWD MAX lifestyle experience platform (fwdmax.fwd.com.hk), allowing the public to gain a deeper understanding of the latest cancer diagnostic and treatment methods.


New trends in precision medicine: jointly enhancing public awareness

Cancer treatment is advancing rapidly, with precision medicine emerging as a key direction for development. Among these advancements, Comprehensive Genomic Profiling (CGP) can analyse multiple cancer types simultaneously, delving into the genomic alterations of a patient's tumour to formulate more precise and personalised treatment plans. This technology helps doctors accurately match patients with targeted therapies and monitor genomic changes during tumour resistance, recurrence, and metastasis to adjust treatment strategies, thereby improving patient outcome.

Through FWD MAX, FWD will publish a series of cancer-related content, including the latest developments in CGP and precision medicine, aiming to increase public awareness and improve understanding of cancer and precision medicine. Oncologists from HKSH Cancer Centre will also share knowledge of cancer precision medicine on FWD MAX, further enhancing public understanding of CGP.

Beyond insurance: FWD expands healthcare partner network to strengthen professional health support

Ken Lau, Managing Director of Greater China and Hong Kong Chief Executive Officer, FWD, said, "FWD is committed to collaborating with medical institutions to provide the public with more comprehensive and forward-looking health protection and support services, covering prevention, treatment, and recovery. As cancer becomes increasingly prevalent and poses a major health challenge in Hong Kong, we are pleased to partner with Roche Diagnostics and HKSH Cancer Centre to enhance public awareness of CGP, an advanced diagnostic technology. Through FWD MAX, the public will have access to reliable information on cancer treatment technologies and healthcare content, supporting them in navigating cancer risks."

Ronald Lo, General Manager of Roche Diagnostics (Hong Kong) Limited, said, "Roche Diagnostics is committed to leveraging innovative medical technology to explore more advanced diagnostic methods for cancer patients. We are honoured to partner with FWD and HKSH Cancer Centre. Through promoting Comprehensive Genomic Profiling, we hope to enhance public understanding of precision medicine in Hong Kong, enabling more patients to receive appropriate treatment and have more choices and better treatment outcomes on their anti-cancer journey.²"

HKSH Cancer Centre's genetic testing guides personalised precision treatment

HKSH Cancer Centre is currently the only private medical institution in Hong Kong offering in-house CGP testing with the entire process from tissue sampling, laboratory testing to data analysis conducted on-site. In-house CGP test enables the detection of mutations in over 300 cancer-related genes in a single assay without the need to send samples to overseas laboratories, significantly shortening turnaround time. HKSH's dedicated pathology team can also provide reports with a clear and in-depth narrative offering specific guidance for doctors to formulate timely and targeted treatment strategies, maximising the potential for personalised and precise cancer care.

Dr Joseph Chan, Chief Medical Officer of HKSH Medical Group and Deputy Medical Superintendent of Hong Kong Sanatorium & Hospital, said, "HKSH Cancer Centre strives to provide patients with comprehensive one-stop services for cancer screening, diagnosis, treatment and rehabilitation. In addition to a top-notch medical team, HKSH is also equipped with cutting-edge medical technologies, such as the first proton therapy system in the Greater Bay Area and we are also Hong Kong's only private medical institution offering in-house CGP service. We believe that CGP is the key to achieving precise and personalised cancer management. Based on genetic test results and patient conditions, doctors can provide critical analysis at the time of cancer diagnosis, relapse, or metastasis, thus formulating highly effective and personalised treatment plans. Whether patients need to undergo surgery, chemotherapy, proton therapy, stereotactic radiotherapy, targeted therapy, hormonal therapy, cellular therapy, or immunotherapy, our multidisciplinary medical team will provide the most comprehensive and compassionate support throughout the treatment and recovery process."

[1] The Hong Kong Cancer Registry of the Hospital Authority, "Overview of Cancer Statistics in Hong Kong, 2022"
[2] For informational use only; this is not a substitute for professional medical advice. Please consult your doctor or qualified healthcare provider for any health concerns.